Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Consensus Rating of “Moderate Buy” by Brokerages

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) has earned a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $39.00.

Several research analysts have recently weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $41.00 price objective on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, July 21st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, May 26th. Wedbush lifted their price objective on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a report on Monday, May 11th. Finally, Wall Street Zen lowered shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th.

Artiva Biotherapeutics Stock Up 0.9%

Shares of NASDAQ:ARTV traded up $0.09 during midday trading on Thursday, reaching $10.11. 18,337 shares of the company were exchanged, compared to its average volume of 387,401. Artiva Biotherapeutics has a fifty-two week low of $2.22 and a fifty-two week high of $14.53. The stock has a fifty day simple moving average of $8.92 and a two-hundred day simple moving average of $7.45. The firm has a market cap of $249.92 million, a PE ratio of -2.86 and a beta of 2.18.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Friday, May 8th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). As a group, analysts forecast that Artiva Biotherapeutics will post -2.45 earnings per share for the current year.

Insider Transactions at Artiva Biotherapeutics

In other Artiva Biotherapeutics news, Director Ra Capital Management, L.P. purchased 41,319 shares of the stock in a transaction on Friday, July 24th. The shares were purchased at an average cost of $9.99 per share, for a total transaction of $412,776.81. Following the purchase, the director owned 17,283,802 shares of the company’s stock, valued at approximately $172,665,181.98. This represents a 0.24% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last quarter, insiders have acquired 9,862,190 shares of company stock valued at $107,232,294 and have sold 53,040 shares valued at $477,890. Insiders own 21.40% of the company’s stock.

Institutional Trading of Artiva Biotherapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ARTV. Dimensional Fund Advisors LP bought a new stake in Artiva Biotherapeutics during the first quarter worth about $131,000. Sanctuary Advisors LLC bought a new position in Artiva Biotherapeutics in the first quarter valued at approximately $139,000. Simplify Asset Management Inc. acquired a new position in shares of Artiva Biotherapeutics during the 1st quarter worth approximately $150,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Artiva Biotherapeutics during the 4th quarter worth approximately $91,000. Finally, Marshall Wace LLP bought a new stake in shares of Artiva Biotherapeutics during the 4th quarter worth approximately $341,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.